Jonathan Doty, DO
Neurology · Dearborn Heights, MINPI 1205495975
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Sanofi at 54.7% of the total.
Across 103 payments — averaging $296.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$17K
- TG Therapeutics, Inc.$7K
- Genentech USA, Inc.$5K
- EMD Serono, Inc.$516
- Amgen$387
- Biogen$250
- plus $1K from 19 others
What the payments were for
- Consulting fees$10,73335%
- Speaking & faculty fees$12,35240%
- Travel & lodging$3,44311%
- Food & beverage$3,94013%
- Education$1130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 10 | $16,723 |
| TG Therapeutics, Inc. | 18 | $6,698 |
| Genentech USA, Inc. | 9 | $4,951 |
| EMD Serono, Inc. | 16 | $516 |
| Amgen(2 entities) | 10 | $387 |
| Biogen | 4 | $250 |
| E.r. Squibb & Sons, L.L.C. | 2 | $224 |
| Novartis | 5 | $170 |
| MDD US Operations, LLC | 1 | $112 |
| Lilly USA, LLC | 4 | $60 |
| Sumitomo Pharma America, Inc. | 3 | $59 |
| AstraZeneca | 2 | $57 |
| AbbVie | 2 | $55 |
| Bristol Myers Squibb | 3 | $48 |
| Eisai Inc. | 2 | $44 |
| Lundbeck LLC | 2 | $39 |
| Scilex Pharmaceuticals Inc. | 2 | $36 |
| CSL Behring | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Octapharma USA, Inc. | 1 | $20 |
| Pfizer | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Urogen Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,582 in reported general payments places this provider in the 85th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 12 | $17,328 |
| Levetiracetam | 18 | $2,149 |
| Gabapentin | 28 | $612 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 17 | $538 |
| Lamotrigine | 11 | $460 |
| Memantine Hcl | 13 | $455 |
| Pregabalin | 18 | $392 |
| Clonazepam | 15 | $63 |
Paid to pharmacies, not to this prescriber.
Other neurology in Dearborn Heights
- Aaron EllenbogenFarmington Hills$1.6M
- Matthew HoltzmanWayne$1.4M
- Richard TroschFarmington Hills$1.2M
- Wade CooperAnn Arbor$991K
- Bisena BulicaDetroit$900K
- Julie BurnhamMount Clemens$836K
- Amit MasihOkemos$785K
- Martin BelkinFarmington Hills$712K
- Robert PaceOwosso$693K
- Rosemarie WalchOwosso$563K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.